18F-PSMA-1007 PET/CT examination can noninvasively diagnose and stage the vast majority of prostate cancer
Objective To investigate the application value of PET/CT imaging technology based on 18F-PSMA-1007 in the non-invasive and accurate diagnosis of prostate cancer(PCa).Methods A total of 117 patients with suspected PCa admitted to Meizhou People's Hospital from November 2020 to April 2022 were examined by 18F-PSMA-1007 PET/CT before biopsy.The maximum standardized uptake value of the lesion and liver was measured by delineating the region of interest,and the tumor background ratio(TBR)was calculated with the liver as the background.Combined with the pathological results after biopsy(64 cases of PCa and 53 cases of benign),the TBR differences between benign and malignant diseases were compared,and the ROC curve was drawn to evaluate their diagnostic efficacy,so as to obtain the best cutoff value.Results The TBR level of PCa patients was higher than that of benign patients,and there was significant difference between the two groups(P<0.001).The ROC curve was plotted by TBR to diagnose PCa,and the area under the ROC curve was 0.881(P<0.001),and the sensitivity and specificity were 78.1%and 94.3%,respectively,when the cutoff value was taken as 0.955.Moreover,among the 14 PCa patients with TBR below the cutoff value,7 had developed lymph nodes and/or bone metastases,which could be indirectly diagnosed as PCa.Conclusion 18F-PSMA-1007 PET/CT TBR has a high application value in distinguishing benign and malignant prostate lesions.Using TBR=0.955 as the cut-off value can achieve good diagnostic efficiency.Even if the TBR is lower than the cutoff value,the detection of metastases can be used as a supplementary diagnosis of PCa and further improve the diagnostic accuracy.18F-PSMA-1007 PET/CT examination can noninvasively diagnose and stage the vast majority of PCa.
国家科技期刊平台
NSTL
万方数据
维普
